Otonomy may be shutting down, but the lessons learned there will live on at another biotech working on new treatments for hearing loss.
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq)...
You have to admire Otonomy’s perseverance. The biotech has experienced a series of clinical failures throughout a grueling year but kept the faith in its ear disorder pipeline.
Otonomy Provides Corporate Update
Otonomy has chalked up its second clinical trial failure in the space of a few months, the latest in a mid-stage study of a treatment for hearing loss, and the biotech has now been forced into a review of its “strategic options”.
More than two months ago, Otonomy shifted focus to its phase 2 hearing loss med, hoping that an upcoming readout would be music to the ears of the company’s top brass.
SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests. These results are in contrast to the positive clinical signal observed with 0.3 mg OTO-413 versus placebo in the previous Phase 1/2 and Phase 2a trial cohorts using the same study design and endpoints.
Otonomy Inc. on Monday said it is pulling the plug on OTO-313, its lead product candidate, following the failure of a Phase 2 study in tinnitus, commonly referred to as ringing in the ears.
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...